[go: up one dir, main page]

AU2001296545A1 - Methods of therapy for b-cell malignancies - Google Patents

Methods of therapy for b-cell malignancies

Info

Publication number
AU2001296545A1
AU2001296545A1 AU2001296545A AU9654501A AU2001296545A1 AU 2001296545 A1 AU2001296545 A1 AU 2001296545A1 AU 2001296545 A AU2001296545 A AU 2001296545A AU 9654501 A AU9654501 A AU 9654501A AU 2001296545 A1 AU2001296545 A1 AU 2001296545A1
Authority
AU
Australia
Prior art keywords
antigen
antibody
cell
methods
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296545A
Inventor
Keting Chu
Lorianne Masuoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001296545A1 publication Critical patent/AU2001296545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
AU2001296545A 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies Abandoned AU2001296545A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23755600P 2000-10-02 2000-10-02
US60/237,556 2000-10-02
US60237556 2000-10-02
PCT/US2001/030961 WO2002028480A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies

Publications (1)

Publication Number Publication Date
AU2001296545A1 true AU2001296545A1 (en) 2002-04-15

Family

ID=22894238

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2002211366A Abandoned AU2002211366A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
AU2001296547A Abandoned AU2001296547A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2001296507A Abandoned AU2001296507A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
AU2001296545A Abandoned AU2001296545A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AU2002211366A Abandoned AU2002211366A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
AU2001296547A Abandoned AU2001296547A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2001296507A Abandoned AU2001296507A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies

Country Status (10)

Country Link
US (5) US7288252B2 (en)
EP (3) EP1326896B1 (en)
JP (6) JP4202127B2 (en)
AT (3) ATE541860T1 (en)
AU (4) AU2002211366A1 (en)
CA (2) CA2424296A1 (en)
DE (2) DE60119945T2 (en)
ES (1) ES2357051T3 (en)
PT (1) PT1326896E (en)
WO (4) WO2002028480A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP4202127B2 (en) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド B cell malignancy treatment method using antagonist anti-CD40 antibody
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
DK1682177T3 (en) * 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Use of antagonist anti-CD40 antibodies to treat chronic lymphocytic leukemia
ATE476448T1 (en) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES AND ORGAN TRANSPLANT REJECTION
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE474599T1 (en) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CA2604036A1 (en) 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
HRP20130852T1 (en) * 2005-05-18 2013-10-25 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
BRPI0618208A2 (en) * 2005-11-01 2011-08-23 Novartis Ag use of anti-cd40 antibodies
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
KR101317235B1 (en) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 Antagonist anti-cd40 antibody pharmaceutical compositions
EP2019857B1 (en) * 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
AU2008323815B2 (en) * 2007-11-09 2013-09-19 Novartis Ag Uses of anti-CD40 antibodies
EP2245065A1 (en) * 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AU2010222929B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PT3556774T (en) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anti-cd40 antibodies and uses thereof
EP2688592A4 (en) 2011-03-25 2015-07-22 Baylor Res Inst COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST HEPATITIS C VIRUS
CA2833743A1 (en) * 2011-04-21 2012-10-26 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
CA2855864A1 (en) 2011-11-17 2013-05-23 Gundram Jung Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells
JP2016011258A (en) * 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス Anti-human CD40 monoclonal antibody and use thereof
US10590202B2 (en) 2012-11-19 2020-03-17 Baliopharm Ag Recombinant bispecific antibody binding to CD20 and CD95
JP7037884B2 (en) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート New vaccines for HPV and HPV-related diseases
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
EP3212230B1 (en) 2014-10-29 2021-01-20 Seagen Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
JP6830437B2 (en) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Genetically modified cells, tissues and organs to treat the disease
PT3303395T (en) 2015-05-29 2020-02-20 Abbvie Inc Anti-cd40 antibodies and uses thereof
CN109069621B (en) 2015-09-04 2022-09-06 普里玛托普医疗股份有限公司 Humanized anti-CD 40 antibodies and uses thereof
EP3356532B1 (en) * 2015-09-30 2022-01-19 Janssen Biotech, Inc. Agonistic antibodies specifically binding human cd40 and methods of use
EP4371570A3 (en) 2016-06-08 2024-07-17 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
MA45672A (en) 2016-07-14 2019-05-22 Biontech Ag MULTISPECIFIC ANTIBODIES DIRECTED AGAINST CD40 AND CD137
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3632932A4 (en) 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN108503708B (en) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 Anti-human CD47 antibodies and uses thereof
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
TW202039558A (en) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 Anti-cd40 antibody, antigen-binding fragments and pharmaceutical use thereof
KR20210097750A (en) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 CD40 antibody pharmaceutical compositions and uses thereof
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
NL2022494B1 (en) * 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN115052625B (en) 2019-12-03 2024-11-01 埃沃特克国际有限责任公司 Interferon-related antigen binding protein and its use
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
HRP20250696T1 (en) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROME
EP4305066A1 (en) 2021-03-09 2024-01-17 Genmab A/S Multispecific binding agents against cd40 and cd137 in therapy
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4327257A1 (en) 2021-05-07 2024-02-28 Redkik Oy Risk probability assessment for cargo shipment operations and methods of use thereof
EP4365200A4 (en) * 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2024525758A (en) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US4355023A (en) * 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
DE3773893D1 (en) * 1987-01-17 1991-11-21 Asta Pharma Ag SYNERGISTIC COMBINATION OF AZELASTINE AND THEOPHYLLIN OR AZELASTINE AND BETA MIMETIC.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
JPH06508501A (en) 1990-07-02 1994-09-29 ブリストル―マイアーズ　スクイブ　カンパニー Ligand for CD28 receptor on B cells and method for regulating cell-cell interaction using the ligand
JP3308534B2 (en) 1991-10-25 2002-07-29 イミュネックス・コーポレーション New cytokine
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
CA2139571C (en) 1992-07-07 2006-11-14 Eleanor N. Fish Interferon receptor binding peptides
DK0945465T3 (en) 1992-07-09 2007-01-15 Novartis Vaccines & Diagnostic Antagonistic monoclonal antibodies to human CD40
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2172376C (en) 1993-10-01 2008-11-18 William C. Fanslow, Iii Antibodies to cd40
AU680102B2 (en) 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
WO2000063395A1 (en) 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU1072701A (en) * 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP4202127B2 (en) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド B cell malignancy treatment method using antagonist anti-CD40 antibody

Also Published As

Publication number Publication date
JP2009201523A (en) 2009-09-10
JP2008156339A (en) 2008-07-10
WO2002028481A3 (en) 2003-03-06
PT1326896E (en) 2011-03-03
WO2002028904A3 (en) 2003-02-06
AU2001296507A1 (en) 2002-04-15
ATE327004T1 (en) 2006-06-15
WO2002028481A9 (en) 2003-07-03
WO2002028905A2 (en) 2002-04-11
EP1717251B1 (en) 2012-01-18
US7611708B2 (en) 2009-11-03
US8088383B2 (en) 2012-01-03
EP1322383B1 (en) 2006-05-24
WO2002028481A2 (en) 2002-04-11
EP1326896A2 (en) 2003-07-16
US20090081242A1 (en) 2009-03-26
EP1717251A2 (en) 2006-11-02
CA2424749A1 (en) 2002-04-11
JP4271440B2 (en) 2009-06-03
US20080075727A1 (en) 2008-03-27
EP1717251A3 (en) 2007-11-07
US20040109857A1 (en) 2004-06-10
DE60143535D1 (en) 2011-01-05
WO2002028480A2 (en) 2002-04-11
DE60119945T2 (en) 2007-01-18
EP1322383A2 (en) 2003-07-02
CA2424296A1 (en) 2002-04-11
JP4838831B2 (en) 2011-12-14
US7445780B2 (en) 2008-11-04
ES2357051T3 (en) 2011-04-15
EP1326896B1 (en) 2010-11-24
JP2009019046A (en) 2009-01-29
AU2002211366A1 (en) 2002-04-15
WO2002028480A3 (en) 2002-07-11
US7820170B2 (en) 2010-10-26
JP4202127B2 (en) 2008-12-24
JP2004510752A (en) 2004-04-08
US7288252B2 (en) 2007-10-30
US20110033456A1 (en) 2011-02-10
EP1322383B9 (en) 2006-09-06
ATE541860T1 (en) 2012-02-15
DE60119945D1 (en) 2006-06-29
JP2004517611A (en) 2004-06-17
US20100172912A1 (en) 2010-07-08
ATE489403T1 (en) 2010-12-15
JP2008074870A (en) 2008-04-03
WO2002028904A2 (en) 2002-04-11
AU2001296547A1 (en) 2002-04-15
WO2002028905A3 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2001296545A1 (en) Methods of therapy for b-cell malignancies
EP1684805B8 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
EP1680141B8 (en) Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
AU7031500A (en) Therapeutic quinazoline compounds
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP1682177B8 (en) Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
MY119403A (en) Novel compounds with analgesic effect.
TW200505900A (en) Muscarinic agonists
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
TR200103432T2 (en) Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases.
WO2004019886A3 (en) Methods for up-regulating antigen expression in tumors
AU4209097A (en) Breast carcinoma-associated gene
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
NZ516564A (en) Cancer therapy